NCT04195828已完成2 期
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study
Fujian Medical University1 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2020年6月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- major pathological response
研究概览
简要总结
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-75 years of age
- •Gastric adenocarcinoma was confirmed by pathology（ including histology or cytology）。
- •CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and/or N+ and M0 before operation.
- •measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short diameter≥15mm，scan slice thicknes 5mm）
- •ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;
- •the expected survival time is more than 12 weeks
- •the main organ function is normal, which should meet the following criteria:
- •(1) blood routine examination standards should be met（no blood transfusion within 14 days）
- •a．HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L （2）biochemical examination shall comply with the following criteria：
- •BIL<1.5 normal upper limit ULN
- •ALT and AST<2.5 ULN,GPT≤1.5×ULN
- •Cr≤1 ULN，CCR（creatinine clearance rate）>60ml/min(Cockcroft-Gault formula)
- •women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test。
- •No other clinical studies were conducted before and during the treatment
- •participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.
排除标准
- •Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy
- •Patients with contraindications for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for larger abdominal surgery
- •patients with metastasis
- •Having any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma/allergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin
- •A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation
- •Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection
- •pregnant or lactating women
- •The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure >140 mmHg, diastolic pressure >90 mmHg)
- •With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted between male > 450 ms, women > 470 ms) and cardiac insufficiency
- •Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and unresected gastric primary tumor; patients with the risk of bleeding should take the gastroscopy test, if it is the gastric cancer, and researchers believe that may results in massive digestive tract hemorrhage；coagulation dysfunction (INR(international normalized ratio)>1.5, APTT(activated partial thromboplastin time)>1.5 ULN), with bleeding tendency;
- •Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the NYHA class II heart failure (2) above unstable angina pectoris (3) occurred within 1 year (4) have clinical significance of myocardial infarction (mi) room sex or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled
- •History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia
- •Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g);
- •A person who has previously been allergic to any component of camrilizumab or to any component of the drug under study
- •The researchers consider those who were not suitable for inclusion.
研究组 & 干预措施
Camrelizumab + Apatinib + nab-paclitaxel +S-1
Experimental
Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
干预措施: Camrelizumab (Drug)
Camrelizumab + Apatinib + nab-paclitaxel +S-1
Experimental
Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
干预措施: Apatinib Mesylate (Drug)
Camrelizumab + Apatinib + nab-paclitaxel +S-1
Experimental
Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
干预措施: nab-paclitaxel (Drug)
Camrelizumab + Apatinib + nab-paclitaxel +S-1
Experimental
Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
干预措施: S1 (Drug)
nab-paclitaxel +S-1
Active Comparator
nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
干预措施: nab-paclitaxel (Drug)
nab-paclitaxel +S-1
Active Comparator
nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
干预措施: S1 (Drug)
结局指标
主要结局
major pathological response
时间窗: 4 months
major pathological response（MPR）
次要结局
- R0 resection rate(4 months)
- pathological complete response(4 months)
- Objective response rate(4 months)
研究者
Chang-Ming Huang, Prof.
Director
Fujian Medical University Union Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerLocally Advanced or Metastatic Gastric AdenocarcinomaNCT04572542The First Affiliated Hospital of Xiamen University46
招募中
不适用
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT05409482Meng Chao Hepatobiliary Hospital of Fujian Medical University300
招募中
不适用
Camrelizumab Combined With Apatinib MesylateSolid TumorNCT05380986Henan Cancer Hospital500
Unknown
2 期
The Transformation of Locally Advanced Pancreatic Cancer.Locally Advanced Pancreatic CancerNCT04723030Peking University30
Unknown
1 期
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIbTransformed LymphomaEBV-Positive DLBCL, NosALK-Positive Anaplastic Large Cell LymphomaNCT04476459Huiqiang Huang33